Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Serum Assay Evaluated for Celiac Disease Screening

By LabMedica International staff writers
Posted on 07 Jun 2015
Celiac Disease (CD) is an autoimmune enteropathy triggered by the ingestion of gluten-containing grains in genetically susceptible individuals and it damages the small intestine mucosa leading to villous atrophy, crypt hyperplasia and intraepithelial lymphocytic infiltrate.

Small bowel biopsy is the conventional gold standard for the diagnosis of CD, but greater emphasis is now given to serological assays like anti-tissue Transglutaminase immunoglobulin (Ig) A antibodies (anti-tTGA), anti-Deamidated Gliadin Peptides IgA and IgG antibodies (a-DGP IgA/IgG) and anti-Endomysium IgA antibodies (EMA).

Scientists at the University of Naples Federico II (Italy) selected 730 children aged between six months and four years nominated Group A: 652 non-CD and 78 CD, and 348 children younger than two years nominated Group B: 327 non-CD and 21 CD which were part of Group A. These groups were used to evaluate the agreement between anti-tTGA and a-DGP IgA/IgG by Kappa coefficient and to compare the diagnostic accuracy of anti-tTGA with that of a-DGP IgA/IgG by Receiver Operating Characteristic (ROC) curve analysis.

Sera from the groups were assayed for IgA and IgG antibodies a-DGP and IgA antibodies anti-tTG by enzyme-linked immunosorbent assay (ELISA) test (Delta Biologicals; Rome, Italy). The IgA antibodies anti-Endomysium were detected by Delta Biological’s Indirect Immunofluorescence (IFI) assay using sections of distal monkey esophagus mounted on glass slides at a starting dilution of 1:5, which was considered the threshold for positivity.

There was a substantial agreement between anti-tTGA and a-DGP IgA in Group A and an almost perfect agreement in Group B. The strength of agreement between anti-tTGA and a-DGP IgG was moderate in Group A and substantial in Group B. The anti-tTGA was more sensitive and specific than a-DGP IgA/IgG in both groups. The strongest point of the current study was the cutoff values being adjusted for the study population in case of all antibody assays according to Receiver Operator Characteristic (ROC) curve analysis.

The authors concluded that anti-tTGA, because of their high diagnostic accuracy, may be used as initial screening assay for CD in all subjects from six months of age, according to new European Society of Pediatric Gastroenterology Hepatology and Nutrition (ESPGHAN) Criteria 2012. The study was published on June 15, 2015, in the journal Clinica Chimica Acta.

Related Links:

University of Naples Federico II
Delta Biologicals 



Gold Member
Veterinary Hematology Analyzer
Exigo H400
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Coagulation Analyzer
CS-2400
New
Piezoelectric Micropump
Disc Pump
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: The tiny clay-based materials can be customized for a range of medical applications (Photo courtesy of Angira Roy and Sam O’Keefe)

‘Brilliantly Luminous’ Nanoscale Chemical Tool to Improve Disease Detection

Thousands of commercially available glowing molecules known as fluorophores are commonly used in medical imaging, disease detection, biomarker tagging, and chemical analysis. They are also integral in... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Delivers Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Pathology

view channel
Image: The ready-to-use DUB enzyme assay kits accelerate routine DUB activity assays without compromising data quality (Photo courtesy of Adobe Stock)

Sensitive and Specific DUB Enzyme Assay Kits Require Minimal Setup Without Substrate Preparation

Ubiquitination and deubiquitination are two important physiological processes in the ubiquitin-proteasome system, responsible for protein degradation in cells. Deubiquitinating (DUB) enzymes contain around... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.